Scrip
Face to face: Ex-Novartis manager takes two-step approach to women's health at Lumavita
12 January 2010
Eleanor Malone
Please Login to read the full article.
12 January 2010
Eleanor Malone
Many pharmaceutical and biotech companies devote themselves to the discovery and development of novel drugs for unmet medical needs. However, with R&D costs and regulatory hurdles multiplying, and much of the low-hanging therapeutic fruit already picked, a growing number of firms are...
Please Login to read the full article.
RELATED CONTENT
NEWS
- The outlook is rosy for the most flexible and adaptable, pharma business leaders agree
- WHO reveals H1N1 committee's links with big pharma
- Onyx plans to file carfilzomib for multiple myeloma on Phase II data
- Pfizer withdraws leukaemia drug Mylotarg from US market on safety and efficacy concerns
COMMENT
Other Informa Comment
FEATURES
- Face to Face with Sandoz's "growth guy" Jeff George
- Recipharm sees opportunity to ride wave of CDMO consolidation
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
